Drug intelligence / Profile preview

Qufeng Shengshi Fang + loratadine

Development stage: Preclinical
Lead developer: Peking Union Medical College Hospital
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of Qufeng Shengshi Fang, a traditional Chinese medicine formulation containing cicada slough and bombyx batryticatus, and loratadine, a second-generation antihistamine. This combination appears to be studied for the treatment of allergic rhinitis. Loratadine works by blocking histamine receptors, reducing allergy symptoms such as sneezing, runny nose, and itchy eyes, while Qufeng Shengshi Fang may provide complementary effects through traditional Chinese medicine principles.

Targets

HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Qufeng Shengshi Fang + loratadine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qufeng Shengshi Fang + loratadine.

Explore the full profile